Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Radiation Injuries 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thymoma 1Thymic epithelial tumor 1Squamous Cell Carcinoma of Head and Neck 1Nasopharyngeal Carcinoma 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × Heavy Ion Radiotherapy × Clear all
NCT05229614 2024-08-21

ICONIC

CNAO National Center of Oncological Hadrontherapy

Phase 2 Recruiting
27 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡